Loading organizations...
Single Technologies is a deep tech company based in Stockholm, focused on fundamentally transforming data generation within sequencing through its patented 3-D Sequencing™ technology. The company develops a novel single-molecule-sensitive 3D sequencing system, integrating expertise from biotechnology, fiber optics, electronics, and material science to push the limits of biological data acquisition and analysis. This approach aims to digitize biological samples with unprecedented detail and speed.
The company was founded in 2014 by Johan Strömqvist, Bengt Sahlgren, and Annika Bolind Bågenholm. Its inception stemmed from a unique combination of advanced research from the Royal Institute of Technology and developments in the fiber optical grating industry. Dr. Strömqvist, with a background in biological physics and single-molecule imaging, was driven by the insight to revolutionize biological sample digitization, leading to the design and patenting of their rapid 3D imaging system.
Single Technologies aims to serve the life sciences and genomics sectors by providing advanced tools for data-driven biology. The company’s long-term vision is to establish high-quality, multidimensional digital formats of biological samples as the industry standard, thereby enabling a new era where biological insights are primarily derived from comprehensive digital data.
Single Technologies has raised $8.0M across 1 funding round.
Single Technologies has raised $8.0M in total across 1 funding round.
Single Technologies is a Stockholm-based deep tech company specializing in advanced DNA sequencing solutions through their proprietary 3-D Sequencing technology. Their platform integrates innovations in single molecule imaging, fluidics, optics, and nanotechnology to enable rapid, high-resolution sequencing with improved speed, capacity, and reagent efficiency. They primarily serve researchers, innovators, and companies in genomics and biotechnology, aiming to remove bottlenecks in sequencing data generation and empower scientists with AI-driven tools to solve complex biological problems. The company has demonstrated growth momentum by raising approximately $4.7 million from investors such as JovB Holding, Sciety, and KTH Holdings, and is preparing for a significant Series A funding round in early 2026 to support commercial rollout of a genomics data production facility[1][2][3][5].
Founded in 2012 by Johan Strömqvist (CEO), Bengt Sahlgren, Annika Bolind Bågenholm, and Raoul Stubbe, Single Technologies emerged from a unique blend of PhD research in single molecule imaging and biotechnology at the Royal Institute of Technology (KTH) and R&D expertise in fiber optical grating technology from the founders’ prior experience with Proximion. The idea originated from combining these scientific and engineering disciplines to push the limits of genomics by developing a new sequencing platform that leverages 3-D imaging and automated fluidics. Early traction included recognition by industry leaders in genomics and securing strategic funding, as well as advisory support from genomics pioneer Bob Kain, formerly of Illumina, which underscores their credibility and potential in the sequencing market[1][2][3].
Single Technologies is positioned at the intersection of genomics, biotechnology, and AI-driven data analysis, riding the wave of increasing demand for large-scale, high-quality sequencing data. The timing is critical as the genomics field faces bottlenecks in data generation speed and cost, which their 3-D Sequencing technology directly addresses. Market forces such as the growth of personalized medicine, drug discovery, and biological research amplify the need for scalable sequencing platforms. By enabling faster and more efficient sequencing, Single Technologies influences the broader ecosystem by accelerating innovation, facilitating new biological insights, and potentially disrupting established sequencing technologies dominated by companies like Illumina[1][2][3][4].
Looking ahead, Single Technologies is preparing for a substantial Series A funding round in early 2026, which will support the commercial rollout of their genomics data production facility. This expansion is expected to accelerate adoption of their 3-D Sequencing platform and broaden their impact in genomics research and diagnostics. Future trends shaping their journey include continued integration of AI for data analysis, increasing demand for multi-dimensional sequencing data, and the push towards more cost-effective, high-throughput sequencing solutions. Their influence is likely to grow as they enable new applications in omics and personalized medicine, potentially reshaping the sequencing landscape by offering a novel, scalable alternative to existing technologies[2][3][5].
In summary, Single Technologies stands out by combining cutting-edge optical and fluidic innovations to overcome current sequencing limitations, empowering scientists to unlock new dimensions in genomics research.
Single Technologies has raised $8.0M in total across 1 funding round.
Single Technologies's investors include B Capital Group, FinTech Collective.
Single Technologies has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in November 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2020 | $8.0M Seed | B Capital Group, FinTech Collective |